First Header Logo Second Header Logo

Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients.

Stratta RJ, Alloway RR, Lo A, Hodge EE. Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplant Proc. 2005 Oct; 37(8):3527-30.

View in: PubMed